Abstract. Since the late 1970s, pharmaceutical R&D has grown at a rapid rate relative to sales and other variables. In this paper, we examine the determinants of pharmaceutical R&D using a pooled data sample of 11 major drug ®rms over the period 1974 to 1994. We ®nd that expected returns and cash¯ows are important explanatory variables of ®rm research intensities during this period. This is consistent with our results for an earlier sample period characterized by very dierent growth patterns on R&D.
Introduction
In an earlier paper, we examined the determinants of pharmaceutical R&D outlays in the United States for the period spanning the early 1960s through the mid 1970s (Grabowski and Vernon, 1981) . This period was characterized by a dramatic decline in new drug introductions together with relatively stagnant growth in R&D expenditures. The drug industry was adjusting to increased regulatory controls and other factors during this time. In our regression analyses, we found that lagged returns on R&D and cash¯ow availability were important determinants of R&D investment behavior. In particular, we found that lagged R&D returns exhibited a signi®cant downward overall trend during this period and this, in turn, exerted an important restraining eect on R&D investment outlays.
In this paper, we examine the determinants of pharmaceutical R&D for the more recent time period 1974 to 1994. In contrast with the earlier one, this period has been characterized by a rapid growth in industry R&D expenditures. Since the late 1970s, R&D expenditures have grown at more than 10% annually in real terms (PhRMA, 1997) . Furthermore, R&D-to-sales percentages have increased by several percentage points. We wish to examine the factors underlying these dramatic changes in R&D investment behavior. For this purpose, we utilize an analytical model with the same basic structure as the one employed in our earlier paper.
The plan of the paper is as follows. In the next section, we review past work, together with recent trends and developments. The following sections present our model and the empirical ®ndings. The ®nal section considers policy implications and discusses important issues for continuing academic research.
Evolution of pharmaceutical R&D: prior work and current trends

The post-1962 period
In our earlier paper, we examined the determinants of ®rm research intensities (R&D-to-sales ratios) for a pooled sample of ten drug ®rms over the period 1962±1975. This was a period in which ®rm research intensities exhibited a moderately declining overall trend. This was in contrast to the earlier post-World War II period in which ®rm research intensities were expanding over time.
A major event in 1962 was the passage of Kefauver-Harris Amendments to the Food, Drug and Cosmetic Act. This occurred in the aftermath of the Thalidomide incident.
1 This 1962 law created the investigational new drug (IND) process and the requirement that all new drugs demonstrate proof of ecacy as well as safety before FDA approval (Wardell and Lasagna, 1975) . The FDA took several years to implement fully all of the changes from the 1962 law. Several academic studies were performed analyzing industry development times and R&D costs during this period. They found that development times increased by several years after 1962, and R&D costs per new drug introduction also increased several fold (Baily, 1972; Wardell and Lasagna, 1975) .
A key determinant of research intensities in our model is the expected return on R&D. With R&D times and costs per NCE rising signi®cantly during the post-62 period, it is plausible to postulate the returns on R&D would be falling. In our earlier analysis of R&D determinants, we utilized a proxy measure of the expected returns on R&D. The numerator of this measure was a ®rm's sales of its recent new drug introductions and the
